| Gene symbol | CSF2 | Synonyms | CSF, GMCSF | Type of gene | protein-coding |
| Chromosome | 5 | Map location | 5q31.1 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | colony stimulating factor 2 | ||||
| GTO ID | GTC0026 |
| Trial ID | NCT00289016 |
| Disease | Melanoma |
| Altered gene | GMCSF |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | Gene transfer |
| Treatment | Talimogene Laherparepvec|Imlygic|T-VEC|JS1 34.5-hGMCSF 47- pA- |
| Phase | Phase2 |
| Recruitment status | Completed |
| Title | A Phase II Study of the Efficacy, Safety and Immunogenicity of OncoVEX^GM-CSF in Patients With Stage IIIc and Stage IV Malignant Melanoma |
| Year | 2006 |
| Country | United Kingdom|United States |
| Company sponsor | BioVex Limited |
| Other ID(s) | 002/03 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||||||
|
|||||||||||||